Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial.
Saved in:
| Title: | Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial. |
|---|---|
| Authors: | Epaulard O; Université Grenoble Alpes, Infectiologie, CHU Grenoble Alpes, France., Carré M; Université Grenoble Alpes, Hématologie, CHU Grenoble Alpes, France., Hermet E; Hématologie, CHU de Clermont-Ferrand, France., Corbin V; Infectiologie, CHU de Clermont-Ferrand, France., Tavernier E; Hématologie, CHU de St Etienne, France., Botelho-Nevers E; Infectiologie, CHU de St Etienne, France., Daguindau E; Hématologie, CHU de Besançon, France., Brunel AS; Infectiologie, CHU de Besançon, France., Rohrlich PS; Hématologie, CHU de Nice, France., Risso K; Infectiologie, CHU de Nice, France., Gallet S; Université Grenoble Alpes, Infectiologie, CHU Grenoble Alpes, France., Gonnet N; Université Grenoble Alpes, CIC1406-INSERM, Université Grenoble Alpes, France., Touati S; Université Grenoble Alpes, Infectiologie, CHU Grenoble Alpes, France., Manceau M; Université Grenoble Alpes, CIC1406-INSERM, Université Grenoble Alpes, France., Thiebault A; Université Grenoble Alpes, Hématologie, CHU Grenoble Alpes, France. |
| Source: | PloS one [PLoS One] 2025 Oct 27; Vol. 20 (10), pp. e0335224. Date of Electronic Publication: 2025 Oct 27 (Print Publication: 2025). |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial |
| Language: | English |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Francisco, CA : Public Library of Science |
| MeSH Terms: | Hematopoietic Stem Cell Transplantation* , Hepatitis B Vaccines*/immunology , Hepatitis B Vaccines*/administration & dosage , Haemophilus Vaccines*/immunology , Haemophilus Vaccines*/administration & dosage , Antibodies, Bacterial*/blood , Antibodies, Bacterial*/immunology , Antibody Formation*/immunology, Humans ; Middle Aged ; Male ; Female ; Prospective Studies ; Hepatitis B/prevention & control ; Hepatitis B/immunology ; Tetanus/prevention & control ; Tetanus/immunology ; Adult ; Poliomyelitis/prevention & control ; Poliomyelitis/immunology ; Vaccination ; Transplantation, Homologous ; Diphtheria/prevention & control ; Diphtheria/immunology |
| Abstract: | Competing Interests: The authors have declared that no competing interests exist. Introduction: National and international guidelines recommend vaccinating hematopoietic stem cell transplant (HSCT) recipients, although relatively few studies have evaluated immunogenicity in adults. We therefore aimed to assess the immune response in adult allogeneic HSCT recipients vaccinated against tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b. Method: We conducted a multicenter prospective study. HSCT recipients were included at least 6 months post-transplantation (maximum: 24 months) if blood CD19 + lymphocytes were ≥0.1 G/L and plasma immunoglobulin ≥ 4g/L, and if no immunosuppressive therapy was applied. They received the hexavalent pediatric combination vaccine for tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b (and pertussis) at months 0, 1, 2, and 12 (in addition to other recommended vaccines). Plasma antibodies against the five valences were quantified at inclusion and 1 month after the third and fourth doses. Results: We included 104 HSCT recipients (median age: 58 years [IQR:48-64]). Study vaccination was initiated a median of 11 months [IQR:9-14] after transplantation. Median [IQR] values for CD19 and plasma gammaglobulin at inclusion were 0.3 [0.2-0.6] G/L and 7.9 [6.4-11.1] g/L, respectively. Seroprotection after three doses and after the M12 booster was achieved for 97.2% and 97.5% of participants for tetanus, 100% and 97.5% for diphtheria, 96.6% and 92.7% for poliomyelitis, 78.3% and 84.1% for hepatitis B, and 94.6% and 95.0% for H. influenzae b. Adverse effects were benign. Conclusion: Vaccination against these five infections initiated during the first year post-allograft is immunogenic and should be performed in every recipient not undergoing immunosuppressive therapy. Trial Registration: ClinicalTrials.gov NCT03402776. (Copyright: © 2025 Epaulard et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
| References: | Pediatr Transplant. 2014 Dec;18(8):882-8. (PMID: 25243374) Bull Cancer. 2024 Feb;111(2S):S40-S49. (PMID: 37479644) Vaccine. 2021 Jul 30;39(33):4742-4750. (PMID: 34049733) Biol Blood Marrow Transplant. 2008 Sep;14(9):1022-1030. (PMID: 18721765) EJHaem. 2022 Feb 17;3(2):484-487. (PMID: 35313664) Clin Transplant. 2003 Oct;17(5):438-43. (PMID: 14703927) Bone Marrow Transplant. 2007 Feb;39(3):179-88. (PMID: 17211432) Bone Marrow Transplant. 2000 Sep;26(6):633-8. (PMID: 11035369) Ann Oncol. 2018 Jun 1;29(6):1354-1365. (PMID: 29688266) J Infect. 2023 Jan;86(1):1-8. (PMID: 36400155) Clin Infect Dis. 2014 Feb;58(3):e44-100. (PMID: 24311479) Clin Vaccine Immunol. 2010 Jul;17(7):1055-65. (PMID: 20463105) Biol Blood Marrow Transplant. 2015 Dec;21(12):2160-2166. (PMID: 26271191) Ann Hematol. 2020 Aug;99(8):1895-1906. (PMID: 32519092) Blood. 1996 Jan 15;87(2):818-26. (PMID: 8555508) Clin Exp Immunol. 2012 Jan;167(1):15-25. (PMID: 22132880) Blood. 2003 Feb 1;101(3):831-6. (PMID: 12393732) Blood. 1996 Apr 1;87(7):3012-8. (PMID: 8639924) Vaccine. 2017 Jun 5;35(25):3286-3294. (PMID: 28487056) Exp Hematol. 2005 Apr;33(4):480-6. (PMID: 15781339) Blood. 2006 Oct 1;108(7):2470-5. (PMID: 16763208) J Clin Immunol. 1998 May;18(3):193-201. (PMID: 9624578) Transplant Cell Ther. 2023 Apr;29(4):275.e1-275.e5. (PMID: 36720458) Bone Marrow Transplant. 1998 Oct;22(8):735-41. (PMID: 9827969) Biol Blood Marrow Transplant. 2020 Sep;26(9):1729-1737. (PMID: 32428736) Clin Infect Dis. 2007 Mar 1;44(5):625-34. (PMID: 17278051) Biol Blood Marrow Transplant. 2017 Sep;23(9):1437-1446. (PMID: 28495643) Bone Marrow Transplant. 1999 Sep;24(6):671-8. (PMID: 10490735) Blood. 2015 Apr 30;125(18):2855-64. (PMID: 25742699) Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. (PMID: 21820392) Bone Marrow Transplant. 1997 May;19(9):933-8. (PMID: 9156269) Biol Blood Marrow Transplant. 2009 Dec;15(12):1523-30. (PMID: 19896075) Lancet Infect Dis. 2019 Jun;19(6):e200-e212. (PMID: 30744963) |
| Molecular Sequence: | ClinicalTrials.gov NCT03402776 |
| Substance Nomenclature: | 0 (Hepatitis B Vaccines) 0 (Haemophilus Vaccines) 0 (Antibodies, Bacterial) |
| Entry Date(s): | Date Created: 20251027 Date Completed: 20251027 Latest Revision: 20251030 |
| Update Code: | 20251030 |
| PubMed Central ID: | PMC12558451 |
| DOI: | 10.1371/journal.pone.0335224 |
| PMID: | 41144397 |
| Database: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Competing Interests: The authors have declared that no competing interests exist.<br />Introduction: National and international guidelines recommend vaccinating hematopoietic stem cell transplant (HSCT) recipients, although relatively few studies have evaluated immunogenicity in adults. We therefore aimed to assess the immune response in adult allogeneic HSCT recipients vaccinated against tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b.<br />Method: We conducted a multicenter prospective study. HSCT recipients were included at least 6 months post-transplantation (maximum: 24 months) if blood CD19 + lymphocytes were ≥0.1 G/L and plasma immunoglobulin ≥ 4g/L, and if no immunosuppressive therapy was applied. They received the hexavalent pediatric combination vaccine for tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b (and pertussis) at months 0, 1, 2, and 12 (in addition to other recommended vaccines). Plasma antibodies against the five valences were quantified at inclusion and 1 month after the third and fourth doses.<br />Results: We included 104 HSCT recipients (median age: 58 years [IQR:48-64]). Study vaccination was initiated a median of 11 months [IQR:9-14] after transplantation. Median [IQR] values for CD19 and plasma gammaglobulin at inclusion were 0.3 [0.2-0.6] G/L and 7.9 [6.4-11.1] g/L, respectively. Seroprotection after three doses and after the M12 booster was achieved for 97.2% and 97.5% of participants for tetanus, 100% and 97.5% for diphtheria, 96.6% and 92.7% for poliomyelitis, 78.3% and 84.1% for hepatitis B, and 94.6% and 95.0% for H. influenzae b. Adverse effects were benign.<br />Conclusion: Vaccination against these five infections initiated during the first year post-allograft is immunogenic and should be performed in every recipient not undergoing immunosuppressive therapy.<br />Trial Registration: ClinicalTrials.gov NCT03402776.<br /> (Copyright: © 2025 Epaulard et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
|---|---|
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0335224 |